Teduglutide

What is Teduglutide?

Teduglutide is a GLP-2 (glucagon-like peptide-2) analogue that promotes intestinal mucosal growth and adaptation. It is FDA-approved for adults and children with short bowel syndrome (SBS) who are dependent on parenteral nutrition. It is the first drug to address the underlying intestinal insufficiency rather than just managing symptoms.

What Teduglutide Is Investigated For

Teduglutide is investigated and FDA-approved for short bowel syndrome (SBS) with intestinal failure in adults and children dependent on parenteral nutrition, and the strongest evidence — backed by the STEPS, STEPS-2, and STEPS-3 pivotal trials — is for reducing parenteral support requirements by stimulating intestinal mucosal growth. It is the first and only disease-modifying therapy for SBS, addressing the underlying intestinal insufficiency rather than managing symptoms. The honest caveats are narrow but important. Long-term colorectal neoplasia risk from chronic intestinotrophic stimulation is still being surveilled through postmarketing registries, the benefit is treatment-dependent and regresses if therapy stops, and the drug is not a general 'gut health' or leaky-gut treatment — its safety profile (required colonoscopic surveillance, pancreatic and biliary monitoring, six-figure annual cost) does not support off-label use for milder GI conditions. Pilot data exists for enterocutaneous fistula but indications outside SBS remain early-stage.

History & Discovery

Teduglutide is the first marketed therapy designed around the biology of glucagon-like peptide-2 (GLP-2), a 33-amino-acid intestinal hormone discovered in the mid-1990s by Daniel Drucker and colleagues at the University of Toronto, who showed it had potent intestinotrophic activity in rodents. Native GLP-2 is degraded within minutes by dipeptidyl peptidase-4 (DPP-4), making it impractical as a therapeutic. NPS Pharmaceuticals (later acquired by Shire, then Takeda) developed teduglutide by substituting the position-2 alanine for glycine, conferring DPP-4 resistance and extending half-life from approximately 7 minutes for native GLP-2 to about 2 hours for teduglutide. The pivotal STEPS trials demonstrated that daily subcutaneous teduglutide could reduce parenteral support requirements in adults with short bowel syndrome (SBS) dependent on parenteral nutrition — a small, severely affected patient population for whom no disease-modifying therapy had previously existed. The FDA approved teduglutide as Gattex in December 2012 for adult SBS, with a pediatric indication added in 2019. Outside the US it is marketed as Revestive. Teduglutide also has the unusual distinction of being one of the most expensive drugs in the world on a per-patient-year basis — list prices have run into the hundreds of thousands of dollars annually — reflecting both rare-disease economics and the drug's status as the only approved therapy for its indication.

How It Works

Teduglutide tells the intestinal lining to grow. For patients who have lost most of their intestine, it helps the remaining gut tissue become more efficient at absorbing nutrients and fluids.

Teduglutide activates the GLP-2 receptor on intestinal subepithelial myofibroblasts, triggering release of growth factors (KGF, IGF-1, EGF) that stimulate crypt cell proliferation and inhibit enterocyte apoptosis. This increases villus height, crypt depth, and overall mucosal surface area. A glycine substitution at position 2 confers DPP-4 resistance, extending half-life from ~7 minutes (native GLP-2) to ~2 hours. It also increases mesenteric blood flow and reduces gastric motility.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Teduglutide:

• 01Long-term colorectal neoplasia risk — postmarketing surveillance and registry data are accumulating, but the long-term cancer risk from chronic intestinotrophic stimulation in patients treated for years to decades is not fully resolved.
• 02Pediatric outcomes — pediatric approval came in 2019 and longer-term developmental, growth, and quality-of-life outcomes in children treated from young ages continue to be characterized.
• 03Predictors of PN independence — a subset of patients achieve full PN weaning while others reach a partial response; the clinical, anatomic, and biochemical predictors are not fully defined.
• 04Optimal duration — there is no clear answer to whether or when patients who have achieved stable response should attempt teduglutide discontinuation, and how to monitor them if they do.
• 05Cost-effectiveness and access equity — at list price, teduglutide is among the most expensive drugs in the world; real-world health-system access and outcomes remain a meaningful research and policy gap.
• 06Use in non-SBS intestinal failure — pilot data exists for enterocutaneous fistula and other intestinal-insufficiency conditions, but indications outside SBS are not approved and are early-stage.

Forms & Administration

Daily SC injection of 0.05mg/kg. Self-administered via reconstituted vial. Treatment duration is ongoing with periodic reassessment. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Teduglutide is FDA-approved for short bowel syndrome with intestinal failure. The dosing here reflects approved labeling. It is not appropriate for off-label use in non-SBS conditions outside of investigational trial settings.

Timeline of Effects

Common Questions

Who Teduglutide Is NOT For

Drug & Supplement Interactions

Teduglutide's most important drug-interaction effects are pharmacodynamic rather than metabolic, because it is a peptide cleared by peptidase-mediated degradation rather than CYP enzymes. The defining clinical interaction is with parenteral nutrition itself: as intestinal absorption improves on teduglutide, the patient's PN volume and electrolyte composition must be reduced to avoid fluid overload, hyperkalemia, and other complications. This is not an adverse drug interaction in the conventional sense but a planned clinical adjustment central to teduglutide management. By increasing intestinal absorption, teduglutide may increase the absorption of orally administered medications. This is clinically relevant for patients on narrow-therapeutic-index drugs, including levothyroxine, some anticonvulsants, and immunosuppressants. Dose monitoring and adjustment may be required. DPP-4 inhibitors used in diabetes (sitagliptin, linagliptin, others) could theoretically prolong endogenous GLP-2 activity, though teduglutide itself is DPP-4 resistant by design, so this is more relevant for native GLP-2 biology than for the drug. Co-administration has not been a focus of regulatory concern.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions